_m2-evolving-landscape-of-parp-inhibitors-in-mcrpc-combination-with-anti-androgens.jpg "M2 - Evolving landscape of PARP inhibitors in mCRPC: combination with anti-androgens from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 41 sec
✓ Published: 17-Jan-2023
✓ Published: 17-Jan-2023
Description:
In this video you'll learn about PARP inhibitors in prostate cancer, in particular the rationale behind combination treatment with anti-androgens from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno.nnWe are pleased to share that this video is part of a micro learning programme that is endorsed by ZERO Prostate Cancer and EAUN.You can find out more about ZERO at https://zerocancer.org/ and EAUN at https://nurses.uroweb.org/nnThe micro learning programme includes videos
In this video you'll learn about PARP inhibitors in prostate cancer, in particular the rationale behind combination treatment with anti-androgens from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno.nnWe are pleased to share that this video is part of a micro learning programme that is endorsed by ZERO Prostate Cancer and EAUN.You can find out more about ZERO at https://zerocancer.org/ and EAUN at https://nurses.uroweb.org/nnThe micro learning programme includes videos
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_metastatic-castration-resistant-prostate-cancer-updates-from-asco-2019.webp "Dr Neal Shore, Dr Joaquin Mateo and Dr Karim Fizazi discuss the treatment and management of metastatic castration resistant prostate cancer (mCRPC). nnDr Shore provides and overview of the current treatment landscape for mCRPC before Dr Mateo summarises the TOPARP-A study and results of the TOPARP-B study presented at ASCO 2019. The panel then go on to discuss ongoing trials including PROFOUND and TRITON3 as well as summarising the ARAMIS and VISION studies.nnThe session concludes with Dr Mateo")
⏲ 13 min 83 sec ✓ 06-Jun-2019
_advances-in-prostate-cancer-in-the-last-10-years-and-a-glimpse-to-the-future.webp "Prof Laura-Maria Krabbe (University of Muenster Medical Center, Muenster, Germany), Prof Karim Fizazi (Institut Gustave Roussy, Villejuif, France) and Prof Johann De Bono (The Institute of Cancer Research, London, UK) discuss the advances in prostate cancer in the last 10 years and offer a glimpse of the future. nnInitially, Prof Krabbe discusses abiraterone and enzalutamide in mCRPC (post docetaxel and pre docetaxel) and their impact for mCRPC care. Prof Fizazi and Prof De Bono then discuss the")
⏲ 20 min 30 sec ✓ 24-Sep-2021
_targeting-advanced-prostate-cancer-with-parp-inhibitors-who-when-and-how.webp "GU CONNECT members, Assoc. Prof. Tanya Dorff (USA) and Prof. Gerhardt Attard (UK) along with guest expert Prof. Fred Saad (Canada) were joined by participants from around the world to discuss targeting advanced prostate cancer with PARP inhibitors: Who, When and How?n nThere was a very interesting and dynamic discussion about:nThe efficacy and safety profiles of PARP inhibitors for patients with prostate cancer and the safety profile in other tumour typesnImplementation of testing strategies to")
⏲ 31 min 97 sec ✓ 15-Mar-2022
_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.webp "Prof Rana McKay (The University of California, San Diego, USA), Prof Gunhild von Amsberg (Martini Clinic, Hamburg, Germany) and Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France) discuss the latest in PARP inhibitors in prostate cancer. nnThe panel analyses the secondary datasets from trials such as PROPEL 2, TALAPRO 2 and MAGNITUDE and discuss how it impacts our understanding of best practice with the use of PARP inhibitors in prostate cancer. nnThey cover the r")
_parp-inhibitor-olaparib-added-to-bevacizumab-benefits-women-with-ovarian-cancer-with-and-without-a-brca-mutation.webp "Prof Isabelle Ray-Coquard presents data from the PAOLA-1/ENGOT-ov25 trial during a press conference at the 2019 ESMO congress.nnThis was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php")
⏲ 3 min 31 sec ✓ 28-Sep-2019
_parp-inhibitors-for-castration-resistant-prostate-cancer.webp "Dr Grace A Martin speaks about the use of the PARP inhibitor olaparib for the treatment of metastatic castration-resistant prostate cancer.nnDr Martin provides a background on the use of PARP inhibitors in prostate cancer, explaining why there is a need to find a targeted treatment for these patients. She discusses some of the existing research in this area and reports on recent FDA approvals of PARP inhibitors for the treatment of prostate cancer. nnDr Martin describes her own clinical experien")
_parp-inhibitors-olaparib-and-talazoparib-as-treatment-for-metastatic-breast-cancer.webp "Dr Matteo Lambertini talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about two PARP inhibitor agents that are approved for treatment in metastatic breast cancer.nnHe explains that they have been studied in two similar randomised trials showing similarly promising results.nnDr Lambertini explains that going forward it is key to understand whether these agents can be used in the early setting but that trials are underway researching this.nnSign up to ecance")
⏲ 3 min 10 sec ✓ 18-Jun-2019
_11-new-drug-updates-in-solid-tumors-parp-inhibitors-in-ovarian-cancer-immunotherapeutics-and-other-agents.webp "Edward Li, PharmD, MPH, BCOP, University of New England College of PharmacynnGet updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.nnThis activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology")
⏲ 37 min 60 sec ✓ 09-Jan-2018
_metastatic-castration-resistant-prostate-cancer-updates-from-asco-2019.jpg)
_advances-in-prostate-cancer-in-the-last-10-years-and-a-glimpse-to-the-future.jpg)
_targeting-advanced-prostate-cancer-with-parp-inhibitors-who-when-and-how.jpg)
_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.jpg)
_parp-inhibitor-olaparib-added-to-bevacizumab-benefits-women-with-ovarian-cancer-with-and-without-a-brca-mutation.jpg)
_parp-inhibitors-for-castration-resistant-prostate-cancer.jpg)
_parp-inhibitors-olaparib-and-talazoparib-as-treatment-for-metastatic-breast-cancer.jpg)
_11-new-drug-updates-in-solid-tumors-parp-inhibitors-in-ovarian-cancer-immunotherapeutics-and-other-agents.jpg)
![[+]](/images/menu.gif){kind=small}